Adalimumab in acute sciatica reduces the long-term need for surgery: a 3-year follow-up of a randomised double-blind placebo-controlled trial.

Genevay, S; Finckh, A; Zufferey, P; Viatte, S; Balagué, F; Gabay, C

Genevay, S; Finckh, A; Zufferey, P; Viatte, S; Balagué, F; Gabay, C.

Affiliation

Genevay S; Division of Rheumatology, University Hospitals of Geneva, Switzerland. stephane.genevay@hcuge.ch

Ann Rheum Dis ; 71(4): 560-2, 2012 Apr.

Article in En | MEDLINE | ID: mdl-21998121

Subject(s)

Anti-Inflammatory Agents/therapeutic use; Antibodies, Monoclonal, Humanized/therapeutic use; Sciatica/drug therapy; Acute Disease; Adalimumab; Adult; Anti-Inflammatory Agents/administration & dosage; Antibodies, Monoclonal, Humanized/administration & dosage; Back Pain/etiology; Diskectomy; Double-Blind Method; Female; Follow-Up Studies; Humans; Injections, Subcutaneous; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Sciatica/complications; Sciatica/surgery; Treatment Outcome; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sciatica / Antibodies, Monoclonal, Humanized / Anti-Inflammatory Agents Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: Ann Rheum Dis Year: 2012 Document type: Article Affiliation country: Switzerland Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google